SlideShare a Scribd company logo
Huateng Pharm https://en.huatengsci.com
What is Favipiravir? How Does It
Work for COVID-19?
Coronavirus continues to wreak havoc worldwide and no drug has been found
or manufactured that can cope with it. Some people, such as US President
Donald Trump, have been promoting the "possible" virtue of
hydroxychloroquine, but another drug is attracting scientific attention –
Favipiravir.
What is Favipiravir?
Favipiravir (CAS No.259793-96-9,
6-fluoro-3-hydroxy-2-pyrazinecarboxamide, T-705) is a new type of RNA
polymerase inhibitor, acting on viral genetic copying to prevent its
reproduction. As another weapon for anti-viral treatment of influenza A and B, it
was approved for marketing in Japan in March 2014. Studies have shown that,
in addition to influenza viruses, Favipiravir may also exhibit good antiviral
effects on a variety of RNA viruses, such as Ebola virus, sand virus, Bunia virus,
and rabies virus, etc. The COVID-19 is a coronavirus, a positive-stranded
single-stranded RNA virus with a coat, and from a mechanical perspective,
Favipiravir also has a potential antiviral effect on it.
Mechanisms of Action of Favipiravir
The mechanism by which favipiravir exerts a broad-spectrum antiviral activity
has not been fully elucidated, but the existing evidence supports that it can
selectively and potently inhibit RNA-dependent RNA polymerase (RdRp) of RNA
viruses. Favipiravir undergoes an intracellular phosphoribosylation to be an
active form, favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), which is
recognized as a substrate by RdRp, and inhibits the RNA polymerase activity.
The structure of favipiravir RTP is similar to that of purine, which can compete
with purine for viral RNA polymerase, causing it to be mistakenly recognized by
viral RNA polymerase, and inserted into the viral RNA chain or combined with
the viral RNA polymerase domain to induce fatal mutations, thus preventing
incorporation of nucleotides for viral RNA replication and transcription.
Huateng Pharm https://en.huatengsci.com
Image source: https://www.ncbi.nlm.nih.gov/
Clinical Evidence
There are two published trials for favipiravir for the treatment of COVID-19:
· An open-label, non-randomised trial in Shenzhen (N=80)5 examined the
efficacy of favipiravir (n=35) versus lopinavir/ritonavir (n=45) for treating
COVID-19. Significantly shorter viral clearance time (primary endpoint) was
found for favipiravir versus lopinavir/ritonavir (median 4 days versus 11 days;
p<0.001). Patients receiving favipiravir also showed significant improvement in
chest imaging compared with those receiving lopinavir/ritonavir, with an
improvement rate of 91.43% versus 62.22% (p = 0.004). Fewer adverse
reactions were reported for favipiravir (11.43%) compared to
lopinavir/ritonavir (55.56%) (p><0.01).
· An open-label, randomised trial in Wuhan (N=240)6 examined the efficacy of
favipiravir (n=120) versus arbidol (n=120) for treating COVID-19. There was
no difference in the 7-day clinical recovery rate (primary endpoint) for
favipiravir versus arbidol in the overall population (61.21% versus 51.67%;
p=0.14). However, for a sub-population of non-critical patients without
hypertension or diabetes, the 7-day clinical recovery rate was significantly
better with favipiravir (71.43%; 70/98) versus arbidol (55.86%; 62/111) (p =
0.02).
Huateng Pharm https://en.huatengsci.com
According to other news reports:
· A Japanese health ministry source suggested that favipiravir was not as
effective in patients with more severe symptoms, from their clinical studies of
70 to 80 participants.
· One medical center in South Korea started administration of favipiravir on 22
February and, while the drug has not been approved for treating COVID-19, the
Ministry of Food and Drug Safety (MFDS) in South Korea is considering a
fast-track approval to import favipiravir.
Recommendations from Professional Bodies
The US Food and Drug Administration (FDA) has not specifically approved any
drugs used to treat COVID-19. The World Health Organization (WHO), the
UK National Health Service (NHS) and the Australian health authorities have not
provided any advice on the use of favipiravir. It is also not included in the 7 th
edition of Chinese Guidelines for the Prevention, Diagnosis, and Treatment of
Novel Coronavirus-induced Pneumonia for tentative treatment of COVID-19.
Adverse Reactions
According to reports, no significant adverse reactions have been seen since the
listing of favipiravir. In the clinical study of COVID-19, no obvious adverse
reactions were found.
In the phase III clinical trial of favipiravir in Japan and internationally, a total of
501 patients participated in the evaluation, including 100 cases of adverse
reactions (19.96%). The main adverse reactions included 24 cases of increased
uric acid (4.79%) and 24 cases. Diarrhea (4.79%), 9 cases of neutropenia
(1.80%), 9 cases of aspartate aminotransferase increase (1.80%), 8 cases of
alanine aminotransferase increase (1.60%).
When applying piriravir clinically, attention should be paid to the interaction
with other drugs:
1. When combined with oseltamivir, the plasma concentrations of the two drugs
were not affected.
2. When combined with famciclovir and sulindac, favipiravir may reduce the
efficacy of these drugs.
Huateng Pharm https://en.huatengsci.com
3. When combined with theophylline, the blood concentration of favipiravir
increases, and adverse drug reactions may occur.
4. When used in combination with repaglinide, the blood concentration of
repaglinide increases due to the inhibition of CYP2C8, which may cause side
effects.
5. When combined with pyrazinamide, it can promote the reabsorption of uric
acid by the renal tubules and increase uric acid.
6. When combined with acetaminophen, the risk of liver injury is low, but liver
function needs to be monitored.
7. When used in combination with a substrate for transport protein, favipiravir
has a weak inhibitory effect on P-glycoprotein (P-gp).
Conclusion
Given that favipiravir's public evidence is limited to two open-label trials, further
research is needed to determine its efficacy and safety in patients with
COVID-19. Three clinical trials are planned and the results may be reported in
the coming months. These findings will determine whether favipiravir should be
used more widely in this situation. At present, there is no international
professional body recommending the treatment of COVID-19 with favipiravir.
Hunan Huateng Pharmaceutical Co., Ltd. is a leading pharmaceutical company
focusing on R&D of pharmaceutical intermediates. The company has extensive
experience in the development of new antiviral drugs that can treat epidemic
influenza, H7N9, and H5N1 avian influenza,
including , Favipiravir/Avigan, Remdesivir, Baloxavir Marboxil and others. We
can provide Favipiravir CAS No. 259793-96-9 with best price and high
quality.

More Related Content

What's hot

Coronavirus (covid-19) basic details
Coronavirus (covid-19) basic details Coronavirus (covid-19) basic details
Coronavirus (covid-19) basic details
Ravish Yadav
 
Covid vaccines pdf - 8 nov 2020
Covid vaccines   pdf - 8 nov  2020Covid vaccines   pdf - 8 nov  2020
Covid vaccines pdf - 8 nov 2020
Ana Cespedes, PhD, MBA
 
Hawaii - Vector Control - Who's Who - What's What - Responsible Citizenship
Hawaii - Vector Control - Who's Who - What's What - Responsible CitizenshipHawaii - Vector Control - Who's Who - What's What - Responsible Citizenship
Hawaii - Vector Control - Who's Who - What's What - Responsible Citizenship
Clifton M. Hasegawa & Associates, LLC
 
Latest Update of Covid 19 vaccines pdf
Latest Update of Covid 19 vaccines pdfLatest Update of Covid 19 vaccines pdf
Latest Update of Covid 19 vaccines pdf
Bambang Budiono
 
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITSSUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
Gagan Sharma
 
Top medical advances 2016
Top medical advances 2016Top medical advances 2016
Top medical advances 2016
Prof. Ahmed Mohamed Badheeb
 
Remdesivir RCT in patients with severe Covid-19 (Wuhan). The Lancet
Remdesivir RCT in patients with severe Covid-19 (Wuhan). The LancetRemdesivir RCT in patients with severe Covid-19 (Wuhan). The Lancet
Remdesivir RCT in patients with severe Covid-19 (Wuhan). The Lancet
PROANTIBIOTICOS
 
1
11
Covid seminar
Covid seminarCovid seminar
Covid seminar
Abhishek Mukherjee
 
Hydroxychloroquine final doi_ijaa
Hydroxychloroquine final doi_ijaaHydroxychloroquine final doi_ijaa
Hydroxychloroquine final doi_ijaa
gisa_legal
 
Mylan (Viatris) History and Track Record
Mylan (Viatris) History and Track RecordMylan (Viatris) History and Track Record
Mylan (Viatris) History and Track Record
S S N D Balakrishna Ch
 
Αχιλλέας Γραβάνης, 4th Health Innovation Conference
Αχιλλέας Γραβάνης, 4th Health Innovation ConferenceΑχιλλέας Γραβάνης, 4th Health Innovation Conference
Αχιλλέας Γραβάνης, 4th Health Innovation Conference
Starttech Ventures
 
Journal Club Presentation
Journal Club PresentationJournal Club Presentation
Journal Club Presentation
Dr Rakesh Verma
 
Update on COVID-19 Innovation: Detection and Vaccine
Update on COVID-19 Innovation: Detection and VaccineUpdate on COVID-19 Innovation: Detection and Vaccine
Update on COVID-19 Innovation: Detection and Vaccine
Rohimah Mohamud
 
India's COVID-19 Vaccination Drive
India's COVID-19 Vaccination DriveIndia's COVID-19 Vaccination Drive
India's COVID-19 Vaccination Drive
ChiragJain426
 
Bima oxford-az-vaccine-detailed-position-statement
Bima oxford-az-vaccine-detailed-position-statementBima oxford-az-vaccine-detailed-position-statement
Bima oxford-az-vaccine-detailed-position-statement
CIkumparan
 
Covishield vaccine
Covishield vaccine Covishield vaccine
Covishield vaccine
Deepu Deepika
 
Developing Drug against COVID-19
Developing Drug against COVID-19Developing Drug against COVID-19
Developing Drug against COVID-19
Suhaib Siddiqi
 
Covid19 Vaccination in India
Covid19 Vaccination in IndiaCovid19 Vaccination in India
Covid19 Vaccination in India
Narasimha Reddy Donthi
 
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
SrinivasaReddy137
 

What's hot (20)

Coronavirus (covid-19) basic details
Coronavirus (covid-19) basic details Coronavirus (covid-19) basic details
Coronavirus (covid-19) basic details
 
Covid vaccines pdf - 8 nov 2020
Covid vaccines   pdf - 8 nov  2020Covid vaccines   pdf - 8 nov  2020
Covid vaccines pdf - 8 nov 2020
 
Hawaii - Vector Control - Who's Who - What's What - Responsible Citizenship
Hawaii - Vector Control - Who's Who - What's What - Responsible CitizenshipHawaii - Vector Control - Who's Who - What's What - Responsible Citizenship
Hawaii - Vector Control - Who's Who - What's What - Responsible Citizenship
 
Latest Update of Covid 19 vaccines pdf
Latest Update of Covid 19 vaccines pdfLatest Update of Covid 19 vaccines pdf
Latest Update of Covid 19 vaccines pdf
 
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITSSUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
 
Top medical advances 2016
Top medical advances 2016Top medical advances 2016
Top medical advances 2016
 
Remdesivir RCT in patients with severe Covid-19 (Wuhan). The Lancet
Remdesivir RCT in patients with severe Covid-19 (Wuhan). The LancetRemdesivir RCT in patients with severe Covid-19 (Wuhan). The Lancet
Remdesivir RCT in patients with severe Covid-19 (Wuhan). The Lancet
 
1
11
1
 
Covid seminar
Covid seminarCovid seminar
Covid seminar
 
Hydroxychloroquine final doi_ijaa
Hydroxychloroquine final doi_ijaaHydroxychloroquine final doi_ijaa
Hydroxychloroquine final doi_ijaa
 
Mylan (Viatris) History and Track Record
Mylan (Viatris) History and Track RecordMylan (Viatris) History and Track Record
Mylan (Viatris) History and Track Record
 
Αχιλλέας Γραβάνης, 4th Health Innovation Conference
Αχιλλέας Γραβάνης, 4th Health Innovation ConferenceΑχιλλέας Γραβάνης, 4th Health Innovation Conference
Αχιλλέας Γραβάνης, 4th Health Innovation Conference
 
Journal Club Presentation
Journal Club PresentationJournal Club Presentation
Journal Club Presentation
 
Update on COVID-19 Innovation: Detection and Vaccine
Update on COVID-19 Innovation: Detection and VaccineUpdate on COVID-19 Innovation: Detection and Vaccine
Update on COVID-19 Innovation: Detection and Vaccine
 
India's COVID-19 Vaccination Drive
India's COVID-19 Vaccination DriveIndia's COVID-19 Vaccination Drive
India's COVID-19 Vaccination Drive
 
Bima oxford-az-vaccine-detailed-position-statement
Bima oxford-az-vaccine-detailed-position-statementBima oxford-az-vaccine-detailed-position-statement
Bima oxford-az-vaccine-detailed-position-statement
 
Covishield vaccine
Covishield vaccine Covishield vaccine
Covishield vaccine
 
Developing Drug against COVID-19
Developing Drug against COVID-19Developing Drug against COVID-19
Developing Drug against COVID-19
 
Covid19 Vaccination in India
Covid19 Vaccination in IndiaCovid19 Vaccination in India
Covid19 Vaccination in India
 
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
 

Similar to What is favipiravir how does it work for covid 19

Unveiling the Antiviral Arsenal Navigating the Realm of Fabiflu Tablets.pdf
Unveiling the Antiviral Arsenal Navigating the Realm of Fabiflu Tablets.pdfUnveiling the Antiviral Arsenal Navigating the Realm of Fabiflu Tablets.pdf
Unveiling the Antiviral Arsenal Navigating the Realm of Fabiflu Tablets.pdf
Swati Khanduri
 
Role of antiviral in COVID 19
Role of antiviral in COVID 19Role of antiviral in COVID 19
Role of antiviral in COVID 19
KING KHALED HOSPITAL NAJRAN
 
Journal Club Evaluation (COVID-19).pptx
Journal Club Evaluation (COVID-19).pptxJournal Club Evaluation (COVID-19).pptx
Journal Club Evaluation (COVID-19).pptx
zeinabnm
 
SAHPRA’s guidance on the use of ivermectin in the prophylaxis or treatment of...
SAHPRA’s guidance on the use of ivermectin in the prophylaxis or treatment of...SAHPRA’s guidance on the use of ivermectin in the prophylaxis or treatment of...
SAHPRA’s guidance on the use of ivermectin in the prophylaxis or treatment of...
SABC News
 
EPVC newsletter sixty three-April 2015
EPVC newsletter  sixty three-April 2015EPVC newsletter  sixty three-April 2015
EPVC newsletter sixty three-April 2015
amin mohamed
 
remdesivir pro.pptx
remdesivir pro.pptxremdesivir pro.pptx
remdesivir pro.pptx
HardikVekariya17
 
Molnupiravir.pdf
Molnupiravir.pdfMolnupiravir.pdf
Molnupiravir.pdf
Zainabath Mahnoora
 
Integration of pharmacokinetics (PK)-pharmacodynamics (PD) data to predict th...
Integration of pharmacokinetics (PK)-pharmacodynamics (PD) data to predict th...Integration of pharmacokinetics (PK)-pharmacodynamics (PD) data to predict th...
Integration of pharmacokinetics (PK)-pharmacodynamics (PD) data to predict th...
Ahmed Ali
 
Raltegravir not better than nrt is for refractory HIV
Raltegravir not better than nrt is for refractory HIVRaltegravir not better than nrt is for refractory HIV
Raltegravir not better than nrt is for refractory HIV
Yael Waknine
 
Remdesivir ; Role of remdesivir in COVID 19
Remdesivir ; Role of remdesivir in COVID 19Remdesivir ; Role of remdesivir in COVID 19
Remdesivir ; Role of remdesivir in COVID 19
Shikha Panwar
 
Nejmoa1512610
Nejmoa1512610Nejmoa1512610
Nejmoa1512610
sufa meiludin
 
Prediction of efficacy of repurposed antiviral drugs against COVID-19
Prediction of efficacy of repurposed antiviral drugs against COVID-19Prediction of efficacy of repurposed antiviral drugs against COVID-19
Prediction of efficacy of repurposed antiviral drugs against COVID-19
Ahmed Ali
 
02_IJPBA_1948_21_Revised.pdf
02_IJPBA_1948_21_Revised.pdf02_IJPBA_1948_21_Revised.pdf
02_IJPBA_1948_21_Revised.pdf
BRNSS Publication Hub
 
Piis1473 3099(16)30190-6
Piis1473 3099(16)30190-6Piis1473 3099(16)30190-6
Piis1473 3099(16)30190-6
Dr. Ashaque Husain
 
Treatment options for Corona Virus.pptx
Treatment options for Corona Virus.pptxTreatment options for Corona Virus.pptx
Treatment options for Corona Virus.pptx
Awais irshad
 
Role of Ivermectin and Hydroxychloroquine in COVID 19(SARS-Cornovirus)
Role of Ivermectin and Hydroxychloroquine in COVID 19(SARS-Cornovirus)Role of Ivermectin and Hydroxychloroquine in COVID 19(SARS-Cornovirus)
Role of Ivermectin and Hydroxychloroquine in COVID 19(SARS-Cornovirus)
Bharat Bhushan chawla
 
Drugs being used in the treatment of confirmed covid 19 cases
Drugs being used in the treatment of confirmed covid 19 casesDrugs being used in the treatment of confirmed covid 19 cases
Drugs being used in the treatment of confirmed covid 19 cases
MedicalDevelopment
 
02_IJPBA_1948_21_Revised.pdf
02_IJPBA_1948_21_Revised.pdf02_IJPBA_1948_21_Revised.pdf
02_IJPBA_1948_21_Revised.pdf
BRNSS Publication Hub
 
What is the best drug for COVID-19? The need for randomized controlled trials.
What is the best drug for COVID-19? The need for randomized controlled trials. What is the best drug for COVID-19? The need for randomized controlled trials.
What is the best drug for COVID-19? The need for randomized controlled trials.
Justin Stebbing
 
A comparison of different treatments for Hepatitis C virus
A comparison of different treatments for Hepatitis C virus A comparison of different treatments for Hepatitis C virus
A comparison of different treatments for Hepatitis C virus
ramoncolon96
 

Similar to What is favipiravir how does it work for covid 19 (20)

Unveiling the Antiviral Arsenal Navigating the Realm of Fabiflu Tablets.pdf
Unveiling the Antiviral Arsenal Navigating the Realm of Fabiflu Tablets.pdfUnveiling the Antiviral Arsenal Navigating the Realm of Fabiflu Tablets.pdf
Unveiling the Antiviral Arsenal Navigating the Realm of Fabiflu Tablets.pdf
 
Role of antiviral in COVID 19
Role of antiviral in COVID 19Role of antiviral in COVID 19
Role of antiviral in COVID 19
 
Journal Club Evaluation (COVID-19).pptx
Journal Club Evaluation (COVID-19).pptxJournal Club Evaluation (COVID-19).pptx
Journal Club Evaluation (COVID-19).pptx
 
SAHPRA’s guidance on the use of ivermectin in the prophylaxis or treatment of...
SAHPRA’s guidance on the use of ivermectin in the prophylaxis or treatment of...SAHPRA’s guidance on the use of ivermectin in the prophylaxis or treatment of...
SAHPRA’s guidance on the use of ivermectin in the prophylaxis or treatment of...
 
EPVC newsletter sixty three-April 2015
EPVC newsletter  sixty three-April 2015EPVC newsletter  sixty three-April 2015
EPVC newsletter sixty three-April 2015
 
remdesivir pro.pptx
remdesivir pro.pptxremdesivir pro.pptx
remdesivir pro.pptx
 
Molnupiravir.pdf
Molnupiravir.pdfMolnupiravir.pdf
Molnupiravir.pdf
 
Integration of pharmacokinetics (PK)-pharmacodynamics (PD) data to predict th...
Integration of pharmacokinetics (PK)-pharmacodynamics (PD) data to predict th...Integration of pharmacokinetics (PK)-pharmacodynamics (PD) data to predict th...
Integration of pharmacokinetics (PK)-pharmacodynamics (PD) data to predict th...
 
Raltegravir not better than nrt is for refractory HIV
Raltegravir not better than nrt is for refractory HIVRaltegravir not better than nrt is for refractory HIV
Raltegravir not better than nrt is for refractory HIV
 
Remdesivir ; Role of remdesivir in COVID 19
Remdesivir ; Role of remdesivir in COVID 19Remdesivir ; Role of remdesivir in COVID 19
Remdesivir ; Role of remdesivir in COVID 19
 
Nejmoa1512610
Nejmoa1512610Nejmoa1512610
Nejmoa1512610
 
Prediction of efficacy of repurposed antiviral drugs against COVID-19
Prediction of efficacy of repurposed antiviral drugs against COVID-19Prediction of efficacy of repurposed antiviral drugs against COVID-19
Prediction of efficacy of repurposed antiviral drugs against COVID-19
 
02_IJPBA_1948_21_Revised.pdf
02_IJPBA_1948_21_Revised.pdf02_IJPBA_1948_21_Revised.pdf
02_IJPBA_1948_21_Revised.pdf
 
Piis1473 3099(16)30190-6
Piis1473 3099(16)30190-6Piis1473 3099(16)30190-6
Piis1473 3099(16)30190-6
 
Treatment options for Corona Virus.pptx
Treatment options for Corona Virus.pptxTreatment options for Corona Virus.pptx
Treatment options for Corona Virus.pptx
 
Role of Ivermectin and Hydroxychloroquine in COVID 19(SARS-Cornovirus)
Role of Ivermectin and Hydroxychloroquine in COVID 19(SARS-Cornovirus)Role of Ivermectin and Hydroxychloroquine in COVID 19(SARS-Cornovirus)
Role of Ivermectin and Hydroxychloroquine in COVID 19(SARS-Cornovirus)
 
Drugs being used in the treatment of confirmed covid 19 cases
Drugs being used in the treatment of confirmed covid 19 casesDrugs being used in the treatment of confirmed covid 19 cases
Drugs being used in the treatment of confirmed covid 19 cases
 
02_IJPBA_1948_21_Revised.pdf
02_IJPBA_1948_21_Revised.pdf02_IJPBA_1948_21_Revised.pdf
02_IJPBA_1948_21_Revised.pdf
 
What is the best drug for COVID-19? The need for randomized controlled trials.
What is the best drug for COVID-19? The need for randomized controlled trials. What is the best drug for COVID-19? The need for randomized controlled trials.
What is the best drug for COVID-19? The need for randomized controlled trials.
 
A comparison of different treatments for Hepatitis C virus
A comparison of different treatments for Hepatitis C virus A comparison of different treatments for Hepatitis C virus
A comparison of different treatments for Hepatitis C virus
 

More from DoriaFang

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
DoriaFang
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
DoriaFang
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
DoriaFang
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
DoriaFang
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
DoriaFang
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
DoriaFang
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
DoriaFang
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
DoriaFang
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
DoriaFang
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
DoriaFang
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
DoriaFang
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DoriaFang
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
DoriaFang
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
DoriaFang
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
DoriaFang
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
DoriaFang
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
DoriaFang
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
DoriaFang
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
DoriaFang
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
DoriaFang
 

More from DoriaFang (20)

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 

Recently uploaded

Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
ayushrajshrivastava7
 
Patellar Instability: Diagnosis Management
Patellar Instability: Diagnosis  ManagementPatellar Instability: Diagnosis  Management
Patellar Instability: Diagnosis Management
Dr Nitin Tyagi
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
13. PROM premature rupture of membranes
13.  PROM premature rupture of membranes13.  PROM premature rupture of membranes
13. PROM premature rupture of membranes
TigistuMelak
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
MuskanShingari
 
What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?
Healthmedsrx.com
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Get New Sim
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
Gokuldas Hospital
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
Dr. Deepika's Homeopathy - Gaur City
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Rahul Sen
 

Recently uploaded (20)

Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
 
Patellar Instability: Diagnosis Management
Patellar Instability: Diagnosis  ManagementPatellar Instability: Diagnosis  Management
Patellar Instability: Diagnosis Management
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
13. PROM premature rupture of membranes
13.  PROM premature rupture of membranes13.  PROM premature rupture of membranes
13. PROM premature rupture of membranes
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
 
What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
 

What is favipiravir how does it work for covid 19

  • 1. Huateng Pharm https://en.huatengsci.com What is Favipiravir? How Does It Work for COVID-19? Coronavirus continues to wreak havoc worldwide and no drug has been found or manufactured that can cope with it. Some people, such as US President Donald Trump, have been promoting the "possible" virtue of hydroxychloroquine, but another drug is attracting scientific attention – Favipiravir. What is Favipiravir? Favipiravir (CAS No.259793-96-9, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, T-705) is a new type of RNA polymerase inhibitor, acting on viral genetic copying to prevent its reproduction. As another weapon for anti-viral treatment of influenza A and B, it was approved for marketing in Japan in March 2014. Studies have shown that, in addition to influenza viruses, Favipiravir may also exhibit good antiviral effects on a variety of RNA viruses, such as Ebola virus, sand virus, Bunia virus, and rabies virus, etc. The COVID-19 is a coronavirus, a positive-stranded single-stranded RNA virus with a coat, and from a mechanical perspective, Favipiravir also has a potential antiviral effect on it. Mechanisms of Action of Favipiravir The mechanism by which favipiravir exerts a broad-spectrum antiviral activity has not been fully elucidated, but the existing evidence supports that it can selectively and potently inhibit RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir undergoes an intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), which is recognized as a substrate by RdRp, and inhibits the RNA polymerase activity. The structure of favipiravir RTP is similar to that of purine, which can compete with purine for viral RNA polymerase, causing it to be mistakenly recognized by viral RNA polymerase, and inserted into the viral RNA chain or combined with the viral RNA polymerase domain to induce fatal mutations, thus preventing incorporation of nucleotides for viral RNA replication and transcription.
  • 2. Huateng Pharm https://en.huatengsci.com Image source: https://www.ncbi.nlm.nih.gov/ Clinical Evidence There are two published trials for favipiravir for the treatment of COVID-19: · An open-label, non-randomised trial in Shenzhen (N=80)5 examined the efficacy of favipiravir (n=35) versus lopinavir/ritonavir (n=45) for treating COVID-19. Significantly shorter viral clearance time (primary endpoint) was found for favipiravir versus lopinavir/ritonavir (median 4 days versus 11 days; p<0.001). Patients receiving favipiravir also showed significant improvement in chest imaging compared with those receiving lopinavir/ritonavir, with an improvement rate of 91.43% versus 62.22% (p = 0.004). Fewer adverse reactions were reported for favipiravir (11.43%) compared to lopinavir/ritonavir (55.56%) (p><0.01). · An open-label, randomised trial in Wuhan (N=240)6 examined the efficacy of favipiravir (n=120) versus arbidol (n=120) for treating COVID-19. There was no difference in the 7-day clinical recovery rate (primary endpoint) for favipiravir versus arbidol in the overall population (61.21% versus 51.67%; p=0.14). However, for a sub-population of non-critical patients without hypertension or diabetes, the 7-day clinical recovery rate was significantly better with favipiravir (71.43%; 70/98) versus arbidol (55.86%; 62/111) (p = 0.02).
  • 3. Huateng Pharm https://en.huatengsci.com According to other news reports: · A Japanese health ministry source suggested that favipiravir was not as effective in patients with more severe symptoms, from their clinical studies of 70 to 80 participants. · One medical center in South Korea started administration of favipiravir on 22 February and, while the drug has not been approved for treating COVID-19, the Ministry of Food and Drug Safety (MFDS) in South Korea is considering a fast-track approval to import favipiravir. Recommendations from Professional Bodies The US Food and Drug Administration (FDA) has not specifically approved any drugs used to treat COVID-19. The World Health Organization (WHO), the UK National Health Service (NHS) and the Australian health authorities have not provided any advice on the use of favipiravir. It is also not included in the 7 th edition of Chinese Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia for tentative treatment of COVID-19. Adverse Reactions According to reports, no significant adverse reactions have been seen since the listing of favipiravir. In the clinical study of COVID-19, no obvious adverse reactions were found. In the phase III clinical trial of favipiravir in Japan and internationally, a total of 501 patients participated in the evaluation, including 100 cases of adverse reactions (19.96%). The main adverse reactions included 24 cases of increased uric acid (4.79%) and 24 cases. Diarrhea (4.79%), 9 cases of neutropenia (1.80%), 9 cases of aspartate aminotransferase increase (1.80%), 8 cases of alanine aminotransferase increase (1.60%). When applying piriravir clinically, attention should be paid to the interaction with other drugs: 1. When combined with oseltamivir, the plasma concentrations of the two drugs were not affected. 2. When combined with famciclovir and sulindac, favipiravir may reduce the efficacy of these drugs.
  • 4. Huateng Pharm https://en.huatengsci.com 3. When combined with theophylline, the blood concentration of favipiravir increases, and adverse drug reactions may occur. 4. When used in combination with repaglinide, the blood concentration of repaglinide increases due to the inhibition of CYP2C8, which may cause side effects. 5. When combined with pyrazinamide, it can promote the reabsorption of uric acid by the renal tubules and increase uric acid. 6. When combined with acetaminophen, the risk of liver injury is low, but liver function needs to be monitored. 7. When used in combination with a substrate for transport protein, favipiravir has a weak inhibitory effect on P-glycoprotein (P-gp). Conclusion Given that favipiravir's public evidence is limited to two open-label trials, further research is needed to determine its efficacy and safety in patients with COVID-19. Three clinical trials are planned and the results may be reported in the coming months. These findings will determine whether favipiravir should be used more widely in this situation. At present, there is no international professional body recommending the treatment of COVID-19 with favipiravir. Hunan Huateng Pharmaceutical Co., Ltd. is a leading pharmaceutical company focusing on R&D of pharmaceutical intermediates. The company has extensive experience in the development of new antiviral drugs that can treat epidemic influenza, H7N9, and H5N1 avian influenza, including , Favipiravir/Avigan, Remdesivir, Baloxavir Marboxil and others. We can provide Favipiravir CAS No. 259793-96-9 with best price and high quality.